Ibrutinib, a Bruton’s tyrosine kinase inhibitor, a new risk factor for cryptococcosis

Link to article at PubMed

Med Mal Infect. 2020 Aug 7:S0399-077X(20)30673-9. doi: 10.1016/j.medmal.2020.07.005. Online ahead of print.


PURPOSE: Invasive fungal diseases and especially Cryptococcus neoformans infections are increasingly reported in patients with hematological malignancies receiving ibrutinib, a Bruton's tyrosine kinase inhibitor.

PATIENTS AND METHOD: We reported three additional cases and reviewed 16 previous published cases together with cases from the international pharmacovigilance database.

RESULTS: Patients were mainly treated for chronic lymphocytic leukemia. Cryptococcosis mostly occurred during the first six months (66%) and especially the first two months (44%) of treatment. Clinical presentation is often pulmonary (68%) and the outcome is usually favorable despite ibrutinib continuation.

CONCLUSION: Clinicians must be aware of this infection in patients with hematological malignancies on ibrutinib.

PMID:32777360 | DOI:10.1016/j.medmal.2020.07.005

Leave a Reply

Your email address will not be published.